PINCELL
PinCell , a biotechnology company developing novel therapies for rare dermatological diseases, announced today the appointment of Gabriella Camboni, M.D., as Chief Executive Officer of PinCell and Member of the Board of Directors, and Luigi Costa as Chairman of the Board. Paola Pozzi, Partner at Sofinnova Partners, also joins PinCell’s Board following a successful seed financing of €1.65 million led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan. The financing was part of a series of investments recently made through The Sofinnova Telethon Fund , the largest fund in Italy dedicated to early-stage biotech startups targeting cures for rare and genetic diseases.
Dr. Camboni is a clinical pharmacologist with 18 years of experience in oncology drug development. She is Chief Executive Officer of BiovelocITA, Italy’s first biotech accelerator, co-founded by Sofinnova Partners in 2015. Dr. Camboni is also co-founder and Chief Operating Officer at Ethical Oncology Science (EOS), an Italian startup dedicated to translational medicine in oncology. Previously, Dr. Camboni co-founded and acted as Head of Development at Novuspharma, a biopharma developing innovative treatments for cancer. Both EOS and Novuspharma are part of Sofinnova Partners’ portfolio alumni.
“I am happy to have the opportunity to help develop a game-changing treatment together with an outstanding scientific team and my long-term associates of Sofinnova Partners,” commented Dr. Camboni.
PinCell also bolstered its Board of Directors with the appointment of Luigi Costa as Chairman of the Board. Mr. Costa has over 25 years of international pharmaceutical and biotech experience. He is an Entrepreneur in Residence at Sofinnova Partners and was the CEO of Nordic Nanovector, a biopharma developing novel targeted therapies for cancer. He also served as Board Member of Oncopeptides AS, a clinical stage biotech company developing a new treatment for Multiple Mieloma. Previously Mr. Costa was Regional Head International at Onyx Pharmaceuticals, acquired by Amgen in 2014, and held several leadership positions with Amgen including Head of International Oncology Franchise, General Manager of Italy and President of France, Amgen’s largest market outside the US. He also held various leadership positions of increasing responsibility with Eli Lilly both in Europe and in the US.
“I am very pleased to have the opportunity to support PinCell in the development of its innovative treatment for a severe autoimmune disease. I am confident that PinCell’s outstanding scientific team, together with my colleagues at Sofinnova Partners, will be able to bring a new therapeutic option to patients," said Mr. Costa.
PinCell’s lead program targets a rare autoimmune bullous disease called Pemphigus, which is characterized by blistering and erosions of the skin and mucous membranes. The condition is chronic, debilitating and potentially life-threatening. PinCell’s unique solution uses an innovative mechanism that inhibits the development of the typical skin blisters, without suppressing the immune system. This is a central factor that makes the treatment less prone to immune-related side effects, enabling patients to have a better quality of life.
Ms. Pozzi commented: “We are pleased to invest in this exceptional team of serial entrepreneurs who have significant clinical expertise in dermatological disorders. They have built strong relationships with US pharma-experienced consultants and international patients’ associations.”
The financing secured last month will advance the company’s development of first-in-class anti-inflammatory therapies for the treatment of rare and severe skin diseases with limited therapeutic options.
Carlo Pincelli, M.D., Professor of Dermatology at the University of Modena and Reggio Emilia and Co-founder of PinCell, said: “We are delighted to have secured financing from Sofinnova Partners, an investor with unparalleled authority and expertise in the biotech domain, as well as the support of experienced biotech executives. Together we are confident we will progress towards clinical studies for the benefit of patients suffering from these debilitating skin conditions.”
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe skin diseases with high unmet medical need. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Dr. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200506005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Outpost24 Acquires Infinipoint to Power Its Entry into the Zero Trust Workforce Access Market9.12.2025 08:00:00 CET | Press release
The strategic acquisition strengthens market leadership by unifying user identity with device trust, eliminating security blind spots. Outpost24, a leader in exposure management and identity security, today announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks Outpost24’s entry into the Zero Trust Workforce Access market and enhances its identity security division, Specops, by laying the foundation for a unified approach that evaluates both the user and the device before access is granted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208750630/en/ Ido Erlichman, Chief Executive Officer of Outpost24. As organizations advance their Zero Trust strategies, authentication alone is no longer enough. MFA and SSO confirm who the user is, but they do not validate the security of the device being used. In hybrid environments where employee
VSO Submits VCP v1.0 to Nineteen Regulatory Authorities Across Thirteen Jurisdictions and Completes First Integrated Evaluation in a Production-Like Environment9.12.2025 08:00:00 CET | Press release
The VeritasChain Standards Organization (VSO) announced today that it has submitted the VeritasChain Protocol (VCP) v1.0 to nineteen regulatory authorities across thirteen jurisdictions, including the United States, United Kingdom, European Union, Singapore, Hong Kong, United Arab Emirates (DIFC), Australia, India, South Korea, Switzerland, Brazil, Liechtenstein, and Saudi Arabia. The submissions present VCP v1.0 as a cryptographic audit framework designed to address emerging supervisory requirements under the EU AI Act Article 12 for logging and traceability, and MiFID II / RTS 25 for timestamp integrity and event ordering in AI-driven and algorithmic trading systems. VSO also confirmed the first completed integration of VCP v1.0 within a controlled, production-like evaluation environment operating under its Early Access Program. The environment successfully generated cryptographically linked event chains, immutable hashing, and verifiable proofs using RFC-aligned structures, demonstr
ENGIE and NHOA Energy Expand Their Partnership in Belgium to Build a New 320 MWh Battery Energy Storage System9.12.2025 08:00:00 CET | Press release
The project strengthens the strategic partnership with ENGIE and reinforces NHOA Energy’s long-term commitment to the Benelux markets NHOA Energy, global provider of utility-scale energy storage systems, has been awarded by ENGIE the contracts for the Supply, Commissioning and the Long-Term Service of a new 80 MW / 320 MWh Battery Energy Storage System (BESS) to be installed at the site of ENGIE’s Drogenbos power station, near Brussels. The Drogenbos BESS represents ENGIE’s third large-scale battery asset in Belgium and was selected in the country’s fifth Capacity Remuneration Mechanism (CRM) auction, securing a 15-year contract starting in November 2027. Designed to deliver essential flexibility services to the Belgian grid, enabling greater integration of renewable energy and supporting grid stability at national level, the BESS will be based on NHOA Energy’s NHEXUS platform, including 88 battery containers capable of providing up to 4 hours of discharge, corresponding to the average
2025 Sees Double-digit Increase in Tourists' Spending via Alipay+ in South Korea as Travellers Seek More Local Experiences9.12.2025 07:55:00 CET | Press release
- Total number of Alipay+ QR code payment transactions in South Korea increased 18%, with total payment volume (TPV) growing 16% year-on-year - Beauty clinic, transportation and F&B are some of the fastest-growing categories in spending with Alipay+ Alipay+, Ant International’s global wallet gateway services, revealed an 18% increase in Alipay+-supported QR code payment transactions, with total payment volume (TPV) growing 16% year-on-year in South Korea, as more tourists use Alipay+ partner wallets and bank apps to make digital payments for a range of services, from beauty clinic treatments and transportation to night market food stalls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208351936/en/ Weixiao Jiang, General Manager North Asia and North America, Alipay+, Ant International South Korea is among the top destinations for tourists from regions such as Southeast Asia and the Chinese mainland, with the greatest numb
Interactive Brokers Expands Market Access with United Arab Emirates Equities9.12.2025 07:00:00 CET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the introduction of United Arab Emirates (UAE) equities through two leading exchanges in one of the world’s fastest-growing economic regions. Clients of Interactive Brokers worldwide can now access the Abu Dhabi Securities Exchange (ADX) and the Dubai Financial Market (DFM). This enables investors in the region to trade both local and international markets from a single platform while investors worldwide can build diversified portfolios across asset classes and geographies, including countries in the growing Gulf Cooperation Council (GCC). Interactive Brokers serves a global client base and is uniquely equipped to advance the financial goals of individual and institutional investors worldwide, including those in the Middle East. Adding UAE stocks further expands Interactive Brokers’ market access and enhances the investment opportunities available to local and global investors. Interactive Broker
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom